№ lp_1_2_34259
File format: docx Character count: 30923 File size: 70 KB
Year: 2023
Region / city: Australia
Topic: Vaccination, Immunocompromised individuals, Herpes Zoster
Document type: Government recommendation
Organization: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: PBAC
Target audience: Healthcare professionals, Immunocompromised individuals
Period of validity: From November 1, 2023
Approval date: November 1, 2023
Modification date: September 2023
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
SAFETY DATA SHEET NRS II™ TRANSWAB® MAXIMUM RECOVERY DILUENT
Year: 2026
Region / city: Corsham, Wiltshire, UK
Topic: Safety data sheet for chemical products
Document type: Safety Data Sheet
Organization / institution: Medical Wire & Equipment Co. (Bath) Ltd.
Author: Medical Wire & Equipment Co. (Bath) Ltd.
Target audience: Users handling chemical substances
Effective period: Not specified
Approval date: Not specified
Amendment date: Not specified
Contextual description: A safety data sheet outlining the properties, hazards, first aid measures, firefighting procedures, and storage recommendations for the NRS II™ TRANSWAB® Maximum Recovery Diluent.
Measles, mumps, rubella and varicella (MMRV) vaccine Patient Group Direction (PGD)
Year: 2026
Region / city: England
Topic: Vaccination
Document type: Patient Group Direction (PGD)
Organization: UK Health Security Agency (UKHSA)
Author: Christina Wilson, Dr Vanessa Saliba, David Green
Target audience: Healthcare practitioners
Validity period: 20 January 2026 – 30 November 2028
Approval date: 20 January 2026
Review date: 31 May 2028
Expiry date: 30 November 2028
Note: Change history
Varicella vaccine (live) Patient Group Direction (PGD)
Year: 2025
Region / city: England
Topic: Immunisation, Varicella Vaccine
Document type: Patient Group Direction (PGD)
Organization / institution: UK Health Security Agency (UKHSA)
Author: Christina Wilson, Dr Vanessa Saliba, David Green
Target audience: Healthcare practitioners, Immunisation Programmes
Effective period: 5 January 2025 - 5 January 2027
Approval date: 5 January 2025
Review date: 5 July 2026
Expiry date: 5 January 2027
Version: v2.0
Topics: Shingrix DILUENT varicella